Publications by authors named "B J Monk"
Article Synopsis
- The study analyzes the cost differences in managing hematologic adverse events (AEs) for the individualized starting dose (ISD) versus the fixed starting dose (FSD) of niraparib from a US payer perspective.
- Data from a phase III trial provided AE occurrence rates, and costs were calculated based on 2020 adjustments from a healthcare database.
- Results showed that managing AEs was significantly cheaper with ISD ($6744.93) compared to FSD ($12,987.71), suggesting ISD not only cuts costs but also improves patient safety.
Article Synopsis
- This study examines the combined effects of the PARP inhibitor niraparib and statins on progression-free survival in ovarian cancer patients.
- The analysis of clinical trials showed that patients taking niraparib experienced better progression-free survival compared to those on placebo (13.8 months vs 8.2 months).
- Notably, patients using both niraparib and statins had significantly better outcomes than those on placebo with statins, highlighting potential benefits of combining these treatments and the need for more research in this area.
Introduction: First-line treatment of persistent, recurrent, or metastatic (advanced) cervical cancer in patients who have a combined positive score (CPS) ≥ 1 with pembrolizumab + chemotherapy versus standard-of-care chemotherapy provides meaningful improvements in overall survival. We conducted a cost-effectiveness analysis from a US payer perspective. A societal perspective scenario was also considered, including productivity gains.
View Article and Find Full Text PDFObjective: Our aim was to perform a systematic review and meta-analysis evaluating the efficacy of standard treatment for stage IVB cervical cancer.
Method: Databases were searched for Phase III trials evaluating stage IVB CC patients according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Systematic review included Phase III trials evaluating first-line treatment of stage IVB cervical cancer (CC).